Get the Stockscreener App
2.8879
1.71%
-0.0421
Geron Corp stock is traded at $2.8879, with a volume of 2.11M.
It is down -1.71% in the last 24 hours and down -15.29% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$2.93
Open:
$2.92
24h Volume:
2.11M
Relative Volume:
0.21
Market Cap:
$1.77B
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-9.0247
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
+0.35%
1M Performance:
-15.29%
6M Performance:
-36.84%
1Y Performance:
+52.38%
1-Day Range:
$2.84
$2.94
1-Week Range:
$2.78
$3.09
52-Week Range:
$1.64
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
2.885 | 1.77B | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.88 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.67 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.50 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.76 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.12 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch - Seeking Alpha
Q4 Earnings Preview: Geron Sets Critical Financial Results DateKey Details Inside - StockTitan
Nvest Financial LLC Purchases Shares of 195,741 Geron Co. (NASDAQ:GERN) - MarketBeat
Geron Corp. (NASDAQ: GERN) Faces Decline: What’s Behind the 3.92% Drop? – Market - HPBL
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geron Corp Stock (GERN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Sale |
4.56 |
674,348 |
3,073,004 |
0 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Option Exercise |
1.19 |
287,900 |
341,693 |
155,400 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Sale |
4.63 |
287,900 |
1,334,129 |
0 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Option Exercise |
1.06 |
421,875 |
447,188 |
421,875 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Sale |
4.64 |
421,875 |
1,959,609 |
0 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Option Exercise |
2.54 |
600,000 |
1,524,000 |
600,000 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Sale |
4.00 |
600,000 |
2,400,000 |
600,000 |
| LAWLIS V BRYAN | Director |
May 15 '24 |
Option Exercise |
1.94 |
35,000 |
67,900 |
35,000 |
| LAWLIS V BRYAN | Director |
May 15 '24 |
Sale |
3.75 |
35,000 |
131,250 |
0 |
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):